Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by equities research analysts at Credit Suisse Group in a note issued to investors on Monday, The Fly reports. They currently have a $167.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $201.00. Credit Suisse Group’s price objective would indicate a potential upside of 189.33% from the company’s previous close.
Several other equities analysts have also recently weighed in on ICPT. Royal Bank of Canada raised their price target on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Jefferies Group restated a “buy” rating and set a $135.00 price target (down previously from $275.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. JMP Securities restated an “outperform” rating and set a $140.00 price target (down previously from $150.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Finally, Seaport Global Securities restated a “buy” rating and set a $136.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $138.62.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $57.72 on Monday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 1 year low of $51.53 and a 1 year high of $135.59. The stock has a market capitalization of $1,450.00, a PE ratio of -3.90 and a beta of -2.05.
Large investors have recently bought and sold shares of the company. WFG Advisors LP lifted its stake in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares during the last quarter. QCM Cayman Ltd. bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter valued at approximately $237,000. Birchview Capital LP bought a new stake in shares of Intercept Pharmaceuticals during the 3rd quarter worth approximately $250,000. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of Intercept Pharmaceuticals by 145.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 2,833 shares during the last quarter. 73.78% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/22/credit-suisse-group-reaffirms-outperform-rating-for-intercept-pharmaceuticals-icpt.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.